A randomized, double-blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE with Truvada

Grants and Contracts Details

StatusFinished
Effective start/end date5/1/0810/27/10

Funding

  • Boehringer-Ingelheim: $3,000.00